Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Dec, 2015 | Pages:
42 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Asahi Kasei Pharma Corp. - Product Pipeline Review - 2015 Summary Global Markets Direct's, 'Asahi Kasei Pharma Corp. - Product Pipeline Review - 2015', provides an overview of the Asahi Kasei Pharma Corp.'s pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Asahi Kasei Pharma Corp.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Asahi Kasei Pharma Corp. including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Asahi Kasei Pharma Corp.'s human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Asahi Kasei Pharma Corp.'s pipeline products Reasons to Buy - Evaluate Asahi Kasei Pharma Corp.'s strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Asahi Kasei Pharma Corp. in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Asahi Kasei Pharma Corp.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Asahi Kasei Pharma Corp. and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Asahi Kasei Pharma Corp. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of Asahi Kasei Pharma Corp. and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Asahi Kasei Pharma Corp. Snapshot 5 Asahi Kasei Pharma Corp. Overview 5 Key Information 5 Key Facts 5 Asahi Kasei Pharma Corp. - Research and Development Overview 6 Key Therapeutic Areas 6 Asahi Kasei Pharma Corp. - Pipeline Review 9 Pipeline Products by Stage of Development 9 Pipeline Products - Monotherapy 10 Pipeline Products - Partnered Products 11 Partnered Products/Combination Treatment Modalities 12 Asahi Kasei Pharma Corp. - Pipeline Products Glance 13 Asahi Kasei Pharma Corp. - Late Stage Pipeline Products 13 Pre-Registration Products/Combination Treatment Modalities 13 Phase III Products/Combination Treatment Modalities 14 Asahi Kasei Pharma Corp. - Clinical Stage Pipeline Products 15 Phase II Products/Combination Treatment Modalities 15 Asahi Kasei Pharma Corp. - Early Stage Pipeline Products 16 Preclinical Products/Combination Treatment Modalities 16 Discovery Products/Combination Treatment Modalities 17 Asahi Kasei Pharma Corp. - Drug Profiles 18 zoledronic acid 18 Product Description 18 Mechanism of Action 18 R&D Progress 18 mizoribine 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 thrombomodulin alfa 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 AK-106 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 elcatonin 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 fasudil 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 pentosan polysulfate sodium 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 ATS-8535 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 Small Molecules to Antagonize EP1 Receptor for Overactive Bladder 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 Small Molecule for Rheumatoid Arthritis and Autoimmune Diseases 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 Small Molecules to Inhibit ADAMTS-5 for Osteoarthritis 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 Asahi Kasei Pharma Corp. - Pipeline Analysis 32 Asahi Kasei Pharma Corp. - Pipeline Products by Target 32 Asahi Kasei Pharma Corp. - Pipeline Products by Route of Administration 34 Asahi Kasei Pharma Corp. - Pipeline Products by Molecule Type 35 Asahi Kasei Pharma Corp. - Pipeline Products by Mechanism of Action 36 Asahi Kasei Pharma Corp. - Recent Pipeline Updates 37 Asahi Kasei Pharma Corp. - Dormant Projects 38 Asahi Kasei Pharma Corp. - Discontinued Pipeline Products 39 Discontinued Pipeline Product Profiles 39 teriparatide acetate transdermal patch 39 Asahi Kasei Pharma Corp. - Locations And Subsidiaries 40 Head Office 40 Appendix 41 Methodology 41 Coverage 41 Secondary Research 41 Primary Research 41 Expert Panel Validation 41 Contact Us 41 Disclaimer 42
List of Tables
Asahi Kasei Pharma Corp., Key Information 5 Asahi Kasei Pharma Corp., Key Facts 5 Asahi Kasei Pharma Corp. - Pipeline by Indication, 2015 8 Asahi Kasei Pharma Corp. - Pipeline by Stage of Development, 2015 9 Asahi Kasei Pharma Corp. - Monotherapy Products in Pipeline, 2015 10 Asahi Kasei Pharma Corp. - Partnered Products in Pipeline, 2015 11 Asahi Kasei Pharma Corp. - Partnered Products/ Combination Treatment Modalities, 2015 12 Asahi Kasei Pharma Corp. - Pre-Registration, 2015 13 Asahi Kasei Pharma Corp. - Phase III, 2015 14 Asahi Kasei Pharma Corp. - Phase II, 2015 15 Asahi Kasei Pharma Corp. - Preclinical, 2015 16 Asahi Kasei Pharma Corp. - Discovery, 2015 17 Asahi Kasei Pharma Corp. - Pipeline by Target, 2015 33 Asahi Kasei Pharma Corp. - Pipeline by Route of Administration, 2015 34 Asahi Kasei Pharma Corp. - Pipeline by Molecule Type, 2015 35 Asahi Kasei Pharma Corp. - Pipeline Products by Mechanism of Action, 2015 36 Asahi Kasei Pharma Corp. - Recent Pipeline Updates, 2015 37 Asahi Kasei Pharma Corp. - Dormant Developmental Projects,2015 38 Asahi Kasei Pharma Corp. - Discontinued Pipeline Products, 2015 39
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
